Slingshot members are tracking this event:

Allergan Files Application to FDA for Approval of Oculeve Intranasal Tear Neurostimulator

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details has filed with the U.S. Food and Drug Administration (FDA) the de novo application for the Oculeve Intranasal Tear Neurostimulator device. According to the FDA, this process provides a pathway for medical devices for which general and/or special controls provide a reasonable assurance of safety and effectiveness, but for which there is no legally marketed predicate device.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 18, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Oculeve Intranasal Tear Neurostimulator, Dry Eye Disease